menu
    • menu

    Company profile for Sage Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage is thinking differently about drug development by using a focused, practical and deliberate approach. We responsibly pursue expedited pathways in our efforts to deliver new treatments for CNS disorders.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sage TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Sage Therapeutics 215 First Street Cambridge, MA 02142
    Telephone
    Telephone
    617-299-8380
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sagerx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Supernus Pharmaceuticals Acquires Sage Therapeutics
    Supernus Pharmaceuticals Acquires Sage Therapeutics

    31 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/31/3125022/19871/en/Supernus-Pharmaceuticals-Completes-Acquisition-of-Sage-Therapeutics.html

    GLOBENEWSWIRE
    31 Jul 2025
    Share Share
    Sage Therapeutics Reveals Q2 2025 Financial Results
    Sage Therapeutics Reveals Q2 2025 Financial Results

    30 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250729095274/en/Sage-Therapeutics-Announces-Second-Quarter-2025-Financial-Results

    BUSINESSWIRE
    30 Jul 2025
    Share Share
    Supernus Ends Hart-Scott-Rodino Wait on Sage Tender Offer
    Supernus Ends Hart-Scott-Rodino Wait on Sage Tender Offer

    28 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/28/3122454/19871/en/Supernus-Pharmaceuticals-Announces-Expiration-of-Hart-Scott-Rodino-Waiting-Period-for-Sage-Therapeutics-Inc-Tender-Offer.html

    GLOBENEWSWIRE
    28 Jul 2025
    Share Share
    Sage's Search for Lifeline Ran Into Defiant Biogen CEO
    Sage's Search for Lifeline Ran Into Defiant Biogen CEO

    03 Jul 2025

    // BIOSPACE

    https://www.biospace.com/business/sages-search-for-lifeline-ran-into-defiant-biogen-ceo

    BIOSPACE
    03 Jul 2025
    Share Share
    Sage's roller coaster ends in $561M acquisition by Supernus
    Sage's roller coaster ends in $561M acquisition by Supernus

    17 Jun 2025

    // ENDPNTS

    https://endpoints.news/supernus-to-acquire-sage-therapeutics-for-about-561m/

    ENDPNTS
    17 Jun 2025
    Share Share
    Sage Therapeutics Reports Q1 2025 Financial Results and Updates
    Sage Therapeutics Reports Q1 2025 Financial Results and Updates

    29 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250428466645/en/Sage-Therapeutics-Announces-First-Quarter-2025-Financial-Results-and-Highlights-Pipeline-and-Business-Updates

    BUSINESSWIRE
    29 Apr 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search